Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Long-Term Debt Repayments (2023 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Long-Term Debt Repayments for 3 consecutive years, with $5.4 million as the latest value for Q4 2025.

  • Quarterly Long-Term Debt Repayments rose 41.81% to $5.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $19.9 million through Dec 2025, up 54.4% year-over-year, with the annual reading at $19.9 million for FY2025, 54.4% up from the prior year.
  • Long-Term Debt Repayments for Q4 2025 was $5.4 million at Rhythm Pharmaceuticals, down from $5.6 million in the prior quarter.
  • The five-year high for Long-Term Debt Repayments was $5.6 million in Q3 2025, with the low at $1.3 million in Q2 2023.
  • Average Long-Term Debt Repayments over 3 years is $3.4 million, with a median of $3.2 million recorded in 2024.
  • The sharpest move saw Long-Term Debt Repayments soared 127.64% in 2024, then soared 41.81% in 2025.
  • Over 3 years, Long-Term Debt Repayments stood at $2.6 million in 2023, then surged by 47.94% to $3.8 million in 2024, then skyrocketed by 41.81% to $5.4 million in 2025.
  • According to Business Quant data, Long-Term Debt Repayments over the past three periods came in at $5.4 million, $5.6 million, and $4.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.